gsk-2816126 profile

GSK-2816126: inhibits EZH2 methyltransferase; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	68210102
CHEMBL ID	3287735
CHEBI ID	124921
SCHEMBL ID	12180401
MeSH ID	M0580964

Synonym
CHEBI:124921
FKSFKBQGSFSOSM-QFIPXVFZSA-N ,
n-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-[(1s)-1-methylpropyl]-6-[6-(1-piperazinyl)-3-pyridinyl]-1h-indole-4-carboxamide
bdbm50017293
chembl3287735 ,
SCHEMBL12180401
gsk126
CS-1401
NCGC00347286-01
S7061
1-[(2s)-butan-2-yl]-n-[(4,6-dimethyl-2-oxo-1h-pyridin-3-yl)methyl]-3-methyl-6-(6-piperazin-1-ylpyridin-3-yl)indole-4-carboxamide
gtpl7012
gsk 126
gsk2816126
gsk-126
HY-13470
smr004701327
MLS006010251
1346574-57-9
ezh2 inhibitor
(s)-1-(sec-butyl)-n-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-methyl-6-(6-(piperazin-1-yl)pyridin-3-yl)-1h-indole-4-carboxamide
1h-indole-4-carboxamide, n-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-3-methyl-1-((1s)-1-methylpropyl)-6-(6-(1-piperazinyl)-3-pyridinyl)-
gsk-2816126
(s)-1-sec-butyl-n-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-methyl-6-(6-(piperazin-1-yl)pyridin-3-yl)-1h-indole-4-carboxamide
n-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-3-methyl-1-((1s)-1-methylpropyl)-6-(6-(1-piperazinyl)-3-pyridinyl)-1h-indole-4-carboxamide
W4OGW9QZ97 ,
gsk 2816126 [who-dd]
gsk-2816126a
EX-A499
AKOS027322309
unii-w4ogw9qz97
BCP06129
Q27077865
AS-16379
1-[(2s)-butan-2-yl]-n-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-3-methyl-6-[6-(piperazin-1-yl)pyridin-3-yl]-1h-indole-4-carboxamide
a9g ,
n-[(1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl]-3-methyl-1-[(1s)-1-methylpropyl]-6-[6-(1-piperazinyl)-3-pyridinyl]-1h-indole-4-carboxamide
CCG-269895
nsc780041
nsc-789702
gsk126 hcl
nsc789702
gsk-126 hcl
nsc-780041
DTXSID301025739

Excerpt	Reference	Relevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

Excerpt	Relevance	Reference
"080 μM), and afforded tumor regression when dosed (200 mpk SC BID) in an EZH2 dependent tumor xenograft model."	( Discovery, design, and synthesis of indole-based EZH2 inhibitors. Albrecht, BK; Audia, JE; Balasubramanian, S; Campbell, R; Cook, AS; Cummings, RT; Dakin, LA; Duplessis, M; Gagnon, A; Gehling, VS; Good, AC; Harmange, JC; Iyer, P; Lee, C; Nasveschuk, CG; Normant, E; Trojer, P; Vaswani, RG; Zhao, F, 2015)	0.42
"The MTD of GSK2816126 was established at 2,400 mg, but the dosing method and relatively short half-life limited effective exposure, and modest anticancer activity was observed at tolerable doses."	( Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors. Carver, J; Creasy, CL; Dhar, A; Frey, S; Giulino-Roth, L; Horner, T; Johnson, PWM; Khaled, A; Leonard, JP; Longley, J; Lopez, J; McCabe, MT; Michot, JM; Oh, C; Pene Dumitrescu, T; Ribrag, V; Stern, M; Wang, X; Winter, JN; Yap, TA, 2019)	0.51

Class	Description
piperazines
pyridines	Any organonitrogen heterocyclic compound based on a pyridine skeleton and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
EWS/FLI fusion protein	Homo sapiens (human)	Potency	20.8690	0.0013	10.1577	42.8575	AID1259252; AID1259253; AID1259255; AID1259256
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Polycomb protein EED	Homo sapiens (human)	IC50 (µMol)	0.0160	0.0020	1.2195	8.9000	AID1151968
Polycomb protein SUZ12	Homo sapiens (human)	IC50 (µMol)	0.0160	0.0040	1.6190	8.9000	AID1151968
Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)	IC50 (µMol)	0.0350	0.0003	0.5047	8.9000	AID1151968; AID1240270; AID1240271; AID1240272; AID1774253; AID1774254; AID1816403; AID1854177; AID1868625; AID1882367
Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)	Ki	0.0005	0.0005	0.0317	0.1940	AID1199092; AID1199093; AID1199094; AID1199095; AID1199096; AID1199097; AID1199098; AID1199151
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
spinal cord development	Polycomb protein EED	Homo sapiens (human)
negative regulation of DNA-templated transcription	Polycomb protein EED	Homo sapiens (human)
heterochromatin formation	Polycomb protein EED	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Polycomb protein EED	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Polycomb protein SUZ12	Homo sapiens (human)
cell population proliferation	Polycomb protein SUZ12	Homo sapiens (human)
positive regulation of cell population proliferation	Polycomb protein SUZ12	Homo sapiens (human)
negative regulation of cell differentiation	Polycomb protein SUZ12	Homo sapiens (human)
oligodendrocyte differentiation	Polycomb protein SUZ12	Homo sapiens (human)
random inactivation of X chromosome	Polycomb protein SUZ12	Homo sapiens (human)
facultative heterochromatin formation	Polycomb protein SUZ12	Homo sapiens (human)
G1/S transition of mitotic cell cycle	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
chromatin organization	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
regulation of DNA-templated transcription	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
positive regulation of cell population proliferation	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
positive regulation of epithelial to mesenchymal transition	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
regulation of gliogenesis	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
skeletal muscle satellite cell maintenance involved in skeletal muscle regeneration	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
cardiac muscle hypertrophy in response to stress	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
cerebellar cortex development	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
hippocampus development	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
B cell differentiation	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
keratinocyte differentiation	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
positive regulation of cell migration	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
regulatory ncRNA-mediated heterochromatin formation	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
subtelomeric heterochromatin formation	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
methylation	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
response to estradiol	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
negative regulation of transcription elongation by RNA polymerase II	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
cellular response to trichostatin A	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
protein modification process	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
hepatocyte homeostasis	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
regulation of circadian rhythm	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
positive regulation of MAP kinase activity	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
positive regulation of GTPase activity	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
negative regulation of keratinocyte differentiation	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
negative regulation of gene expression, epigenetic	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
negative regulation of DNA-templated transcription	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
negative regulation of retinoic acid receptor signaling pathway	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
rhythmic process	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
stem cell differentiation	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
negative regulation of striated muscle cell differentiation	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
synaptic transmission, GABAergic	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
cellular response to hydrogen peroxide	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
G1 to G0 transition	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
protein localization to chromatin	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
positive regulation of protein serine/threonine kinase activity	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
regulation of kidney development	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
liver regeneration	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
facultative heterochromatin formation	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
positive regulation of dendrite development	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
negative regulation of cytokine production involved in inflammatory response	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
positive regulation of cell cycle G1/S phase transition	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
response to tetrachloromethane	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
negative regulation of G1/S transition of mitotic cell cycle	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
negative regulation of stem cell differentiation	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
heterochromatin formation	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
transcription corepressor binding	Polycomb protein EED	Homo sapiens (human)
protein binding	Polycomb protein EED	Homo sapiens (human)
enzyme activator activity	Polycomb protein EED	Homo sapiens (human)
histone methyltransferase activity	Polycomb protein EED	Homo sapiens (human)
identical protein binding	Polycomb protein EED	Homo sapiens (human)
nucleosome binding	Polycomb protein EED	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Polycomb protein SUZ12	Homo sapiens (human)
transcription corepressor binding	Polycomb protein SUZ12	Homo sapiens (human)
protein binding	Polycomb protein SUZ12	Homo sapiens (human)
enzyme activator activity	Polycomb protein SUZ12	Homo sapiens (human)
methylated histone binding	Polycomb protein SUZ12	Homo sapiens (human)
histone methyltransferase activity	Polycomb protein SUZ12	Homo sapiens (human)
metal ion binding	Polycomb protein SUZ12	Homo sapiens (human)
lncRNA binding	Polycomb protein SUZ12	Homo sapiens (human)
promoter-specific chromatin binding	Polycomb protein SUZ12	Homo sapiens (human)
chromatin DNA binding	Polycomb protein SUZ12	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
RNA polymerase II core promoter sequence-specific DNA binding	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
transcription corepressor binding	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
chromatin binding	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
transcription corepressor activity	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
protein binding	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
protein-lysine N-methyltransferase activity	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
chromatin DNA binding	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
histone methyltransferase activity	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
ribonucleoprotein complex binding	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
histone H3K27 methyltransferase activity	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
primary miRNA binding	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
lncRNA binding	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
histone H3 methyltransferase activity	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
histone H3K27 trimethyltransferase activity	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
promoter-specific chromatin binding	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
nucleus	Polycomb protein EED	Homo sapiens (human)
nucleoplasm	Polycomb protein EED	Homo sapiens (human)
chromosome	Polycomb protein EED	Homo sapiens (human)
cytosol	Polycomb protein EED	Homo sapiens (human)
ESC/E(Z) complex	Polycomb protein EED	Homo sapiens (human)
nucleus	Polycomb protein SUZ12	Homo sapiens (human)
nucleoplasm	Polycomb protein SUZ12	Homo sapiens (human)
nucleolus	Polycomb protein SUZ12	Homo sapiens (human)
nuclear body	Polycomb protein SUZ12	Homo sapiens (human)
sex chromatin	Polycomb protein SUZ12	Homo sapiens (human)
chromatin silencing complex	Polycomb protein SUZ12	Homo sapiens (human)
ESC/E(Z) complex	Polycomb protein SUZ12	Homo sapiens (human)
ribonucleoprotein complex	Polycomb protein SUZ12	Homo sapiens (human)
RSC-type complex	Polycomb protein SUZ12	Homo sapiens (human)
nucleus	Polycomb protein SUZ12	Homo sapiens (human)
chromosome	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
chromosome, telomeric region	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
nucleus	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
nucleoplasm	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
pronucleus	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
synapse	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
chromatin	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
chromatin silencing complex	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
pericentric heterochromatin	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
ESC/E(Z) complex	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
nucleus	Histone-lysine N-methyltransferase EZH2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (139)

Assay ID	Title	Year	Journal	Article
AID1199107	Selectivity ratio of IC50 for human SETD7 to IC50 for human wild-type EZH2	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Selective inhibitors of protein methyltransferases.
AID1199108	Selectivity ratio of IC50 for human SMYD2 to IC50 for human wild-type EZH2	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Selective inhibitors of protein methyltransferases.
AID1816530	Downregulation of CENPK mRNA expression in human MDA-MB-468 cells at 10 uM incubated for 48 hrs by qRT-PCR analysis
AID1816512	Downregulation of CHEK1 mRNA expression in human MDA-MB-468 cells at 10 uM incubated for 48 hrs by qRT-PCR analysis
AID1816400	PROTAC activity at CRBN E3 ligase/EZH2 in PRC2 complex in human WSUDLCL2 cells assessed as reduction in H3K27me3 level at up to 10 uM incubated for 72 hrs by Western blot analysis
AID1860974	Binding affinity to recombinant PRC2 complex (unknown origin) assessed as association rate constant by surface plasmon resonance assay	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Discovery of precision targeting EZH2 degraders for triple-negative breast cancer.
AID1872379	Antitumor activity against human DLBCL pfeiffer cells xenografted in mouse assessed as tumor growth inhibition at 50 mg/kg, ip administered once daily for 36 days relative to control	2022	European journal of medicinal chemistry, Mar-05, Volume: 231	Recent strategies targeting Embryonic Ectoderm Development (EED) for cancer therapy: Allosteric inhibitors, PPI inhibitors, and PROTACs.
AID1199151	Inhibition of human EZH2 Y641S mutant assessed as H3K27me2 level after 30 mins by scintillation counting analysis in presence of [3H]-SAM	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Selective inhibitors of protein methyltransferases.
AID1816510	Downregulation of ARL6IP mRNA expression in human MDA-MB-468 cells at 10 uM incubated for 48 hrs by qRT-PCR analysis
AID1199097	Inhibition of human EZH2 Y641N mutant assessed as H3K27me2 level after 30 mins by scintillation counting analysis in presence of [3H]-SAM	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Selective inhibitors of protein methyltransferases.
AID1860968	Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Discovery of precision targeting EZH2 degraders for triple-negative breast cancer.
AID1318898	Binding affinity to EZH2 (unknown origin) expressed in baculovirus infected SF9 cells co-expressing SUZ12/EED/RbAp48 complex assessed as binding off-rate at 0.4 uM incubated for 20 mins by Q-TOF mass spectrometry	2016	Journal of medicinal chemistry, Sep-22, Volume: 59, Issue:18	Design and Synthesis of Pyridone-Containing 3,4-Dihydroisoquinoline-1(2H)-ones as a Novel Class of Enhancer of Zeste Homolog 2 (EZH2) Inhibitors.
AID1816403	Inhibition of N-terminal His-tagged EZH2 in human PRC2 complex (2 to end residues) expressed in Sf9 cells using [3H]-SAM as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by AlphaLISA immunodetection assay
AID1816499	Downregulation of ARL6IP mRNA expression in human A549 cells at 10 uM incubated for 48 hrs by qRT-PCR analysis
AID1151977	Cytotoxicity against human U87MG cells assessed as growth inhibition after 72 hrs by WST-1 assay	2014	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 24, Issue:11	Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
AID1199116	Selectivity ratio of IC50 for human DOT1L to IC50 for human wild-type EZH2	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Selective inhibitors of protein methyltransferases.
AID1854193	Antiproliferative activity against human PC-3 cells assessed as inhibition of cell proliferation incubated for 3 to 7 days followed by replacement of medium containing compound every 3 days by CCK8 assay	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Targeting EZH2 for cancer therapy: From current progress to novel strategies.
AID1199098	Inhibition of human EZH2 Y641C mutant assessed as H3K27me2 level after 30 mins by scintillation counting analysis in presence of [3H]-SAM	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Selective inhibitors of protein methyltransferases.
AID1816391	PROTAC activity at CRBN E3 ligase/EZH2 in PRC2 complex in human WSUDLCL2 cells assessed as induction of SUZ12 degradation at 1 uM incubated for 48 hrs by Western blot analysis
AID1860967	Antiproliferative activity against human BT-549 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Discovery of precision targeting EZH2 degraders for triple-negative breast cancer.
AID1199093	Inhibition of human EZH2 A677G mutant assessed as H3K27me0 level after 30 mins by scintillation counting analysis in presence of [3H]-SAM	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Selective inhibitors of protein methyltransferases.
AID1860970	Antiproliferative activity against human MCF-10A cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Discovery of precision targeting EZH2 degraders for triple-negative breast cancer.
AID1816407	Antiproliferative activity against human WSUDLCL2 cells harboring EZH2-Y641F mutant assessed as inhibition of cell growth at 10 uM incubated for 9 days by optical microscopic analysis
AID1240276	Intrinsic clearance in human liver microsomes	2015	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17	Discovery, design, and synthesis of indole-based EZH2 inhibitors.
AID1816506	Downregulation of CEP76 mRNA expression in human NCI-H1299 cells at 10 uM incubated for 48 hrs by qRT-PCR analysis
AID1816390	PROTAC activity at CRBN E3 ligase/EZH2 in PRC2 complex in human WSUDLCL2 cells assessed as induction of RbAp48 degradation at 1 uM incubated for 48 hrs by Western blot analysis
AID1199109	Selectivity ratio of IC50 for human MMSET to IC50 for human wild-type EZH2	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Selective inhibitors of protein methyltransferases.
AID1199112	Selectivity ratio of IC50 for human PRMT3 to IC50 for human wild-type EZH2	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Selective inhibitors of protein methyltransferases.
AID1774254	Inhibition of EZH2 Y641F mutant (unknown origin) using SAM as substrate incubated for 60 mins by luminescence microplate reader assay	2021	Journal of medicinal chemistry, 10-28, Volume: 64, Issue:20	Discovery of IHMT-EZH2-115 as a Potent and Selective Enhancer of Zeste Homolog 2 (EZH2) Inhibitor for the Treatment of B-Cell Lymphomas.
AID1151976	Cytotoxicity against human T98G cells assessed as growth inhibition after 72 hrs by WST-1 assay	2014	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 24, Issue:11	Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
AID1860969	Antiproliferative activity against human HL-60 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Discovery of precision targeting EZH2 degraders for triple-negative breast cancer.
AID1774255	Antiproliferative activity against human WSUDLCL2 cells assessed as inhibition of cell growth measured after 6 days by CellTiter-Glo luminescent assay	2021	Journal of medicinal chemistry, 10-28, Volume: 64, Issue:20	Discovery of IHMT-EZH2-115 as a Potent and Selective Enhancer of Zeste Homolog 2 (EZH2) Inhibitor for the Treatment of B-Cell Lymphomas.
AID1816513	Downregulation of TACC3 mRNA expression in human MDA-MB-468 cells at 10 uM incubated for 48 hrs by qRT-PCR analysis
AID1199105	Selectivity ratio of IC50 for human MLL4 to IC50 for human wild-type EZH2	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Selective inhibitors of protein methyltransferases.
AID1816502	Downregulation of CHEK1 mRNA expression in human A549 cells at 10 uM incubated for 48 hrs by qRT-PCR analysis
AID1868625	Inhibition of wild-type EZH2 (unknown origin)	2022	Journal of medicinal chemistry, 05-26, Volume: 65, Issue:10	Targeting Enhancer of Zeste Homolog 2 for the Treatment of Hematological Malignancies and Solid Tumors: Candidate Structure-Activity Relationships Insights and Evolution Prospects.
AID1854177	Inhibition of EZH2 (unknown origin)	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Targeting EZH2 for cancer therapy: From current progress to novel strategies.
AID1199113	Selectivity ratio of IC50 for human PRMT4 to IC50 for human wild-type EZH2	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Selective inhibitors of protein methyltransferases.
AID1240274	Intrinsic clearance in rat liver microsomes	2015	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17	Discovery, design, and synthesis of indole-based EZH2 inhibitors.
AID1240270	Inhibition of EZH2 (unknown origin) using biotinylated nucleosome, H3K27me3 activator and [3H]-SAM incubated for 60 mins by top-count based method	2015	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17	Discovery, design, and synthesis of indole-based EZH2 inhibitors.
AID1816500	Downregulation of CEP76 mRNA expression in human A549 cells at 10 uM incubated for 48 hrs by qRT-PCR analysis
AID1151974	Cytotoxicity against human Daudi cells assessed as growth inhibition after 72 hrs by WST-1 assay	2014	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 24, Issue:11	Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
AID1199115	Selectivity ratio of IC50 for human PRMT6 to IC50 for human wild-type EZH2	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Selective inhibitors of protein methyltransferases.
AID1151973	Cytotoxicity against human U2932 cells assessed as growth inhibition after 72 hrs by WST-1 assay	2014	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 24, Issue:11	Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
AID1240273	Intrinsic clearance in mouse liver microsomes	2015	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17	Discovery, design, and synthesis of indole-based EZH2 inhibitors.
AID1199102	Selectivity ratio of IC50 for human MLL1 to IC50 for human wild-type EZH2	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Selective inhibitors of protein methyltransferases.
AID1816392	PROTAC activity at CRBN E3 ligase/EZH2 in PRC2 complex in human WSUDLCL2 cells assessed as induction of EED degradation at 1 uM incubated for 48 hrs by Western blot analysis
AID1860966	Antiproliferative activity against human MDA-MB-468 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Discovery of precision targeting EZH2 degraders for triple-negative breast cancer.
AID1816399	PROTAC activity at CRBN E3 ligase/EZH2 in PRC2 complex in human WSUDLCL2 cells assessed as induction of EED degradation at up to 10 uM incubated for 72 hrs by Western blot analysis
AID1774253	Inhibition of EZH2 (unknown origin) using SAM as substrate incubated for 60 mins by luminescence microplate reader assay	2021	Journal of medicinal chemistry, 10-28, Volume: 64, Issue:20	Discovery of IHMT-EZH2-115 as a Potent and Selective Enhancer of Zeste Homolog 2 (EZH2) Inhibitor for the Treatment of B-Cell Lymphomas.
AID1199101	Selectivity ratio of IC50 for human SUV39H2 to IC50 for human wild-type EZH2	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Selective inhibitors of protein methyltransferases.
AID1860971	Antiproliferative activity against human MV4-11 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Discovery of precision targeting EZH2 degraders for triple-negative breast cancer.
AID1199095	Inhibition of human EZH2 Y641F mutant assessed as H3K27me2 level after 30 mins by scintillation counting analysis in presence of [3H]-SAM	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Selective inhibitors of protein methyltransferases.
AID1240271	Inhibition of EZH2 Y641N mutant (unknown origin) using biotinylated nucleosome, H3K27me3 activator and [3H]-SAM incubated for 60 mins by top-count based method	2015	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17	Discovery, design, and synthesis of indole-based EZH2 inhibitors.
AID1199099	Selectivity ratio of IC50 for human G9a to IC50 for human wild-type EZH2	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Selective inhibitors of protein methyltransferases.
AID1816498	Downregulation of BRIC5 mRNA expression in human A549 cells at 10 uM incubated for 48 hrs by qRT-PCR analysis
AID1199094	Inhibition of human EZH2 A677G mutant assessed as H3K27me1 level after 30 mins by scintillation counting analysis in presence of [3H]-SAM	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Selective inhibitors of protein methyltransferases.
AID1199092	Inhibition of human wild-type EZH2 assessed as H3K27me0 level after 30 mins by scintillation counting analysis in presence of [3H]-SAM	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Selective inhibitors of protein methyltransferases.
AID1816516	Antiproliferative activity against human A549 cells harboring SWI/SNF mutant assessed as inhibition of cell growth at 10 uM treated for 9 days by optical microscopic analysis
AID1816511	Downregulation of CEP76 mRNA expression in human MDA-MB-468 cells at 10 uM incubated for 48 hrs by qRT-PCR analysis
AID1240279	Protein binding in dog plasma	2015	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17	Discovery, design, and synthesis of indole-based EZH2 inhibitors.
AID1816517	Antiproliferative activity against human NCI-H1299 cells harboring SWI/SNF mutant assessed as inhibition of cell growth at 10 uM treated for 9 days by optical microscopic analysis
AID1199119	Selectivity ratio of Ki(app) for human EZH1 to Ki(app) for human wild-type EZH2	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Selective inhibitors of protein methyltransferases.
AID1860975	Binding affinity to recombinant PRC2 complex (unknown origin) assessed as dissociation rate constant by surface plasmon resonance assay	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Discovery of precision targeting EZH2 degraders for triple-negative breast cancer.
AID1199117	Selectivity ratio of IC50 for human DNMT3a to IC50 for human wild-type EZH2	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Selective inhibitors of protein methyltransferases.
AID1860973	Antiproliferative activity against human HK-2 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Discovery of precision targeting EZH2 degraders for triple-negative breast cancer.
AID1816507	Downregulation of CHEK1 mRNA expression in human NCI-H1299 cells at 10 uM incubated for 48 hrs by qRT-PCR analysis
AID1816397	PROTAC activity at CRBN E3 ligase/EZH2 in PRC2 complex in human WSUDLCL2 cells assessed as induction of EZH2 degradation at up to 10 uM incubated for 72 hrs by Western blot analysis
AID1240275	Intrinsic clearance in dog liver microsomes	2015	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17	Discovery, design, and synthesis of indole-based EZH2 inhibitors.
AID1860965	Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Discovery of precision targeting EZH2 degraders for triple-negative breast cancer.
AID1860976	Binding affinity to recombinant PRC2 complex (unknown origin) assessed as Equilibrium dissociation constant by surface plasmon resonance assay	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Discovery of precision targeting EZH2 degraders for triple-negative breast cancer.
AID1816504	Downregulation of BRIC5 mRNA expression in human NCI-H1299 cells at 10 uM incubated for 48 hrs by qRT-PCR analysis
AID1151975	Cytotoxicity against human PC3 cells assessed as growth inhibition after 72 hrs by WST-1 assay	2014	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 24, Issue:11	Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
AID1151978	Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by WST-1 assay	2014	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 24, Issue:11	Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
AID1240278	Protein binding in rat plasma	2015	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17	Discovery, design, and synthesis of indole-based EZH2 inhibitors.
AID1240272	Inhibition of EZH2 in human HeLa cells assessed as reduction in H3K27me3 levels incubated for 72 hrs by ELISA method	2015	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17	Discovery, design, and synthesis of indole-based EZH2 inhibitors.
AID1199104	Selectivity ratio of IC50 for human MLL3 to IC50 for human wild-type EZH2	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Selective inhibitors of protein methyltransferases.
AID1199096	Inhibition of human EZH2 Y641H mutant assessed as H3K27me2 level after 30 mins by scintillation counting analysis in presence of [3H]-SAM	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Selective inhibitors of protein methyltransferases.
AID1199118	Selectivity ratio of IC50 for human DNMT3b to IC50 for human wild-type EZH2	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Selective inhibitors of protein methyltransferases.
AID1199106	Selectivity ratio of IC50 for human SETD8 to IC50 for human wild-type EZH2	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Selective inhibitors of protein methyltransferases.
AID1151968	Inhibition of EZH2 histone methyltransferase activity in EZH2/SUZ12/EED protein complex (unknown origin) using histone H3 peptide/S-adenosylmethionine as substrate after 2 hrs by TR-FRET assay	2014	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 24, Issue:11	Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
AID1199110	Selectivity ratio of IC50 for human SETMAR to IC50 for human wild-type EZH2	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Selective inhibitors of protein methyltransferases.
AID1882367	Inhibition of EZH2 (unknown origin)	2022	Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3	Fascinating Transformation of SAM-Competitive Protein Methyltransferase Inhibitors from Nucleoside Analogues to Non-Nucleoside Analogues.
AID1816393	PROTAC activity at CRBN E3 ligase/EZH2 in PRC2 complex in human WSUDLCL2 cells assessed as induction of EZH2 degradation at 1 uM incubated for 48 hrs by Western blot analysis
AID1199103	Selectivity ratio of IC50 for human MLL2 to IC50 for human wild-type EZH2	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Selective inhibitors of protein methyltransferases.
AID1816501	Downregulation of CENPK mRNA expression in human A549 cells at 10 uM incubated for 48 hrs by qRT-PCR analysis
AID1854194	Antiproliferative activity against human SK-OV-3 cells assessed as inhibition of cell proliferation incubated for 3 to 7 days followed by replacement of medium containing compound every 3 days by CCK8 assay	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Targeting EZH2 for cancer therapy: From current progress to novel strategies.
AID1151972	Cytotoxicity against human Pfeiffer cells expressing EZH2 A667G mutant assessed as growth inhibition after 72 hrs by WST-1 assay	2014	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 24, Issue:11	Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
AID1816508	Downregulation of TACC3 mRNA expression in human NCI-H1299 cells at 10 uM incubated for 48 hrs by qRT-PCR analysis
AID1860972	Antiproliferative activity against human L02 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Discovery of precision targeting EZH2 degraders for triple-negative breast cancer.
AID1816404	Downregulation of CENPK mRNA expression in human NCI-H1299 cells at 10 uM incubated for 48 hrs by qRT-PCR analysis
AID1199111	Selectivity ratio of IC50 for human PRMT1 to IC50 for human wild-type EZH2	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Selective inhibitors of protein methyltransferases.
AID1240277	Protein binding in mouse plasma	2015	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17	Discovery, design, and synthesis of indole-based EZH2 inhibitors.
AID1816505	Downregulation of ARL6IP mRNA expression in human NCI-H1299 cells at 10 uM incubated for 48 hrs by qRT-PCR analysis
AID1240280	Protein binding in human plasma	2015	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17	Discovery, design, and synthesis of indole-based EZH2 inhibitors.
AID1816503	Downregulation of TACC3 mRNA expression in human A549 cells at 10 uM incubated for 48 hrs by qRT-PCR analysis
AID1199100	Selectivity ratio of IC50 for human SUV39H1 to IC50 for human wild-type EZH2	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Selective inhibitors of protein methyltransferases.
AID1816398	PROTAC activity at CRBN E3 ligase/EZH2 in PRC2 complex in human WSUDLCL2 cells assessed as induction of SUZ12 degradation at up to 10 uM incubated for 72 hrs by Western blot analysis
AID1816509	Downregulation of BRIC5 mRNA expression in human MDA-MB-468 cells at 10 uM incubated for 48 hrs by qRT-PCR analysis
AID1199114	Selectivity ratio of IC50 for human PRMT5 to IC50 for human wild-type EZH2	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Selective inhibitors of protein methyltransferases.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347149	Furin counterscreen qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347168	HepG2 cells viability qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347152	Confirmatory screen NINDS AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347169	Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347161	Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347153	Confirmatory screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347167	Vero cells viability qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346024	Human enhancer of zeste 2 polycomb repressive complex 2 subunit (2.1.1.43 Histone methyltransferases (HMTs))	2012	Nature, Dec-06, Volume: 492, Issue:7427	EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.
AID1346024	Human enhancer of zeste 2 polycomb repressive complex 2 subunit (2.1.1.43 Histone methyltransferases (HMTs))	2012	Journal of biomolecular screening, Dec, Volume: 17, Issue:10	Development and validation of reagents and assays for EZH2 peptide and nucleosome high-throughput screens.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	59 (60.20)	24.3611
2020's	39 (39.80)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	1 (1.02%)	5.53%
Reviews	6 (6.12%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	1 (1.02%)	0.25%
Other	90 (91.84%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
adenine [no description available]	2.21	1	6-aminopurines; purine nucleobase	Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
astemizole Astemizole: Antihistamine drug now withdrawn from the market in many countries because of rare but potentially fatal side effects.. astemizole : A piperidine compound having a 2-(4-methoxyphenyl)ethyl group at the 1-position and an N-[(4-fluorobenzyl)benzimidazol-2-yl]amino group at the 4-position.	3.51	1	benzimidazoles; piperidines	anti-allergic agent; anticoronaviral agent; H1-receptor antagonist
metformin Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289). metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.	2.25	1	guanidines	environmental contaminant; geroprotector; hypoglycemic agent; xenobiotic
entinostat [no description available]	2.11	1	benzamides; carbamate ester; primary amino compound; pyridines; substituted aniline	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor
nifedipine Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.	3.51	1	C-nitro compound; dihydropyridine; methyl ester	calcium channel blocker; human metabolite; tocolytic agent; vasodilator agent
nimesulide nimesulide: structure. nimesulide : An aromatic ether having phenyl and 2-methylsulfonamido-5-nitrophenyl as the two aryl groups.	2.17	1	aromatic ether; C-nitro compound; sulfonamide	cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
oxyphenbutazone Oxyphenbutazone: A non-steroidal anti-inflammatory drug. Oxyphenbutazone eyedrops have been used abroad in the management of postoperative ocular inflammation, superficial eye injuries, and episcleritis. (From AMA, Drug Evaluations Annual, 1994, p2000) It had been used by mouth in rheumatic disorders such as ankylosing spondylitis, osteoarthritis, and rheumatoid arthritis but such use is no longer considered justified owing to the risk of severe hematological adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p27). oxyphenbutazone : A metabolite of phenylbutazone obtained by hydroxylation at position 4 of one of the phenyl rings. Commonly used (as its hydrate) to treat pain, swelling and stiffness associated with arthritis and gout, it was withdrawn from the market 1984 following association with blood dyscrasis and Stevens-Johnson syndrome.	3.51	1	phenols; pyrazolidines	antimicrobial agent; antineoplastic agent; antipyretic; drug metabolite; gout suppressant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic metabolite
pentamidine Pentamidine: Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of PNEUMOCYSTIS pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects.. pentamidine : A diether consisting of pentane-1,5-diol in which both hydroxyl hydrogens have been replaced by 4-amidinophenyl groups. A trypanocidal drug that is used for treatment of cutaneous leishmaniasis and Chagas disease.	2.41	1	aromatic ether; carboxamidine; diether	anti-inflammatory agent; antifungal agent; calmodulin antagonist; chemokine receptor 5 antagonist; EC 2.3.1.48 (histone acetyltransferase) inhibitor; NMDA receptor antagonist; S100 calcium-binding protein B inhibitor; trypanocidal drug; xenobiotic
pentoxifylline [no description available]	2.1	1	oxopurine
carbon tetrachloride Carbon Tetrachloride: A solvent for oils, fats, lacquers, varnishes, rubber waxes, and resins, and a starting material in the manufacturing of organic compounds. Poisoning by inhalation, ingestion or skin absorption is possible and may be fatal. (Merck Index, 11th ed). tetrachloromethane : A chlorocarbon that is methane in which all the hydrogens have been replaced by chloro groups.	2.31	1	chlorocarbon; chloromethanes	hepatotoxic agent; refrigerant
lysine Lysine: An essential amino acid. It is often added to animal feed.. lysine : A diamino acid that is caproic (hexanoic) acid bearing two amino substituents at positions 2 and 6.. L-lysine : An L-alpha-amino acid; the L-isomer of lysine.	3.57	7	aspartate family amino acid; L-alpha-amino acid zwitterion; L-alpha-amino acid; lysine; organic molecular entity; proteinogenic amino acid	algal metabolite; anticonvulsant; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
cytarabine [no description available]	2.15	1	beta-D-arabinoside; monosaccharide derivative; pyrimidine nucleoside	antimetabolite; antineoplastic agent; antiviral agent; immunosuppressive agent
pyrroles 1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.	2.25	1	pyrrole; secondary amine
indazoles Indazoles: A group of heterocyclic aromatic organic compounds consisting of the fusion of BENZENE and PYRAZOLES.	4.37	5	indazole
isoxazoles Isoxazoles: Azoles with an OXYGEN and a NITROGEN next to each other at the 1,2 positions, in contrast to OXAZOLES that have nitrogens at the 1,3 positions.. isoxazole : A monocyclic heteroarene with a structure consisting of a 5-membered ring containing three carbon atoms and an oxygen and nitrogen atom adjacent to each other. It is the parent of the class of isoxazoles.. isoxazoles : Oxazoles in which the N and O atoms are adjacent.	2.15	1	isoxazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
hydrazine diamine : Any polyamine that contains two amino groups.	2.31	1	azane; hydrazines	EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor
apomorphine hydrochloride, anhydrous [no description available]	3.51	1
azacitidine Azacitidine: A pyrimidine analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent.. 5-azacytidine : An N-glycosyl-1,3,5-triazine that is 4-amino-1,3,5-triazin-2(1H)-one substituted by a beta-D-ribofuranosyl residue via an N-glycosidic linkage. An antineoplastic agent, it is used in the treatment of myeloid leukaemia.	2.11	1	N-glycosyl-1,3,5-triazine; nucleoside analogue	antineoplastic agent
tetradecanoylphorbol acetate Tetradecanoylphorbol Acetate: A phorbol ester found in CROTON OIL with very effective tumor promoting activity. It stimulates the synthesis of both DNA and RNA.. phorbol ester : Esters of phorbol, originally found in croton oil (from Croton tiglium, of the family Euphorbiaceae). A number of phorbol esters possess activity as tumour promoters and activate the mechanisms associated with cell growth. Some of these are used in experiments as activators of protein kinase C.. phorbol 13-acetate 12-myristate : A phorbol ester that is phorbol in which the hydroxy groups at the cyclopropane ring juction (position 13) and the adjacent carbon (position 12) have been converted into the corresponding acetate and myristate esters. It is a major active constituent of the seed oil of Croton tiglium. It has been used as a tumour promoting agent for skin carcinogenesis in rodents and is associated with increased cell proliferation of malignant cells. However its function is controversial since a decrease in cell proliferation has also been observed in several cancer cell types.	2.17	1	acetate ester; diester; phorbol ester; tertiary alpha-hydroxy ketone; tetradecanoate ester	antineoplastic agent; apoptosis inducer; carcinogenic agent; mitogen; plant metabolite; protein kinase C agonist; reactive oxygen species generator
etoposide [no description available]	2.11	1	beta-D-glucoside; furonaphthodioxole; organic heterotetracyclic compound	antineoplastic agent; DNA synthesis inhibitor
adenosine quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit	3.98	3	adenosines; purines D-ribonucleoside	analgesic; anti-arrhythmia drug; fundamental metabolite; human metabolite; vasodilator agent
epigallocatechin gallate epigallocatechin gallate: a steroid 5alpha-reductase inhibitor and antimutagen in green tea (Camellia sinensis). (-)-epigallocatechin 3-gallate : A gallate ester obtained by the formal condensation of gallic acid with the (3R)-hydroxy group of (-)-epigallocatechin.	3.51	1	flavans; gallate ester; polyphenol	antineoplastic agent; antioxidant; apoptosis inducer; geroprotector; Hsp90 inhibitor; neuroprotective agent; plant metabolite
hexamidine hexamidine : A polyether that is the bis(4-guanidinophenyl) ether of hexane-1,6-diol.	2.41	1	aromatic ether; guanidines; polyether	antimicrobial agent; antiseptic drug
triazoles Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.	2.31	1	1,2,3-triazole
3-deazaneplanocin 3-deazaneplanocin: S-adenosylhomocysteine hydrolase antagonist	4.74	4
tanshinone tanshinone: from root of Salvia miltiorrhiza Bunge; RN given refers to tanshinone I; cardioprotective agent and neuroprotective agent	2.1	1	abietane diterpenoid	anticoronaviral agent
przewaquinone d przewaquinone D: isolated from root of Salvia przewalskii; structure given in first source; RN given refers to the trans- isomer, przewaquinone D	2.58	2
tanshinone ii a tashinone IIA: a cardiovascular agent with antineoplastic activity; isolated from Salvia miltiorrhiza; structure in first source	2.1	1	abietane diterpenoid
angiotensin ii Giapreza: injectable form of angiotensin II used to increase blood pressure in adult patients with septic or other distributive shock. Ile(5)-angiotensin II : An angiotensin II that acts on the central nervous system (PDB entry: 1N9V).	2.21	1	amino acid zwitterion; angiotensin II	human metabolite
nsc 663284 NSC 663284: structure in first source	2.11	1	quinolone
bortezomib [no description available]	2.85	3	amino acid amide; L-phenylalanine derivative; pyrazines	antineoplastic agent; antiprotozoal drug; protease inhibitor; proteasome inhibitor
theasinensin a theasinensin A: a tea polyphenol formed from (-)-epigallocatechin gallate, suppresses antibiotic resistance of methicillin-resistant Staphylococcus aureus. theasinensin A : A biflavonoid that is obtained by coupling of two molecules of (-)-epigallocatechin 3-gallate resulting in a bond between positions C-2 of the hydroxyphenyl ring. It is a natural product found in oolong tea.	2.31	1	biflavonoid; gallate ester; proanthocyanidin	anti-inflammatory agent; anticoronaviral agent; apoptosis inducer; EC 3.2.1.20 (alpha-glucosidase) inhibitor; hepatoprotective agent; hypoglycemic agent; melanin synthesis inhibitor; plant metabolite
decitabine [no description available]	3.12	4	2'-deoxyribonucleoside
wedelolactone wedelolactone: antihepatotoxic coumestan from Eclipta prostrata and Wedelia calendulacea (both Asteraceae); structure given in first source. wedelolactone : A member of the class of coumestans that is coumestan with hydroxy substituents as positions 1, 8 and 9 and a methoxy substituent at position 3.	4.43	2	aromatic ether; coumestans; delta-lactone; polyphenol	antineoplastic agent; apoptosis inducer; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; hepatoprotective agent; metabolite
ellagic acid [no description available]	2.11	1	catechols; cyclic ketone; lactone; organic heterotetracyclic compound; polyphenol	antioxidant; EC 1.14.18.1 (tyrosinase) inhibitor; EC 2.3.1.5 (arylamine N-acetyltransferase) inhibitor; EC 2.4.1.1 (glycogen phosphorylase) inhibitor; EC 2.5.1.18 (glutathione transferase) inhibitor; EC 2.7.1.127 (inositol-trisphosphate 3-kinase) inhibitor; EC 2.7.1.151 (inositol-polyphosphate multikinase) inhibitor; EC 2.7.4.6 (nucleoside-diphosphate kinase) inhibitor; EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor; EC 5.99.1.2 (DNA topoisomerase) inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; food additive; fungal metabolite; geroprotector; plant metabolite; skin lightening agent
n'-((1e)-(4-(diethylamino)phenyl)methylene)-4-hydroxybenzohydrazide N'-((1E)-(4-(diethylamino)phenyl)methylene)-4-hydroxybenzohydrazide: structure in first source	2.31	1
ergonovine maleate ergometrine maleate : A maleate salt resulting form the reaction of equimolar amounts of maleic acid and ergometrine. It is used in the active management of the third stage of labour, and to prevent or treat postpartum of postabortal haemorrhage caused by uterine atony: by maintaining uterine contraction and tone, blood vessels in the uterine wall are compressed and blood flow reduced.	3.51	1	maleate salt	diagnostic agent; oxytocic
ganglioside, gd2 [no description available]	2.21	1
bvt.948 [no description available]	2.11	1
idelalisib idelalisib: an antineoplastic agent and p110delta inhibitor; structure in first source. idelalisib : A member of the class of quinazolines that is 5-fluoro-3-phenylquinazolin-4-one in which the hydrogen at position 2 is replaced by a (1S)-1-(3H-purin-6-ylamino)propyl group. used for for the treatment of refractory indolent non-Hodgkin's lymphoma and relapsed chronic lymphocytic leukemia.	2.21	1	aromatic amine; organofluorine compound; purines; quinazolines; secondary amino compound	antineoplastic agent; apoptosis inducer; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
mdv 3100 [no description available]	2.25	1	(trifluoromethyl)benzenes; benzamides; imidazolidinone; monofluorobenzenes; nitrile; thiocarbonyl compound	androgen antagonist; antineoplastic agent
nsc 23766 NSC 23766 trihydrochloride : A hydrochloride resulting from the formal reaction of NSC 23766 with 3 mol eq. of hydrogen chloride. An inhibitor of the signalling G-protein known as RAC1 (Ras-related C3 botulinum toxin substrate 1).. Rac1 inhibitor : Any inhibitor of Rac1.	2.25	1	hydrochloride	antiviral agent; apoptosis inducer; EC 3.6.5.2 (small monomeric GTPase) inhibitor; muscarinic antagonist
olaparib [no description available]	3.51	1	cyclopropanes; monofluorobenzenes; N-acylpiperazine; phthalazines	antineoplastic agent; apoptosis inducer; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
pci 32765 ibrutinib: a Btk protein inhibitor. ibrutinib : A member of the class of acrylamides that is (3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine in which the piperidine nitrogen is replaced by an acryloyl group. A selective and covalent inhibitor of the enzyme Bruton's tyrosine kinase, it is used for treatment of B-cell malignancies.	2.21	1	acrylamides; aromatic amine; aromatic ether; N-acylpiperidine; pyrazolopyrimidine; tertiary carboxamide	antineoplastic agent; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
az 505 AZ 505: an SMYD2 inhibitor; structure in first source	2.11	1
navitoclax [no description available]	2.17	1	aryl sulfide; monochlorobenzenes; morpholines; N-sulfonylcarboxamide; organofluorine compound; piperazines; secondary amino compound; sulfone; tertiary amino compound	antineoplastic agent; apoptosis inducer; B-cell lymphoma 2 inhibitor
bix 01294 [no description available]	3.69	2	piperidines
piperidines Piperidines: A family of hexahydropyridines.	2.61	2
abt-199 venetoclax: A BCL-2 inhibitor with antineoplastic activity that is used in the treatment of CHRONIC LYMPHOCYTIC LEUKEMIA associated with chromosome 17p deletion; structure in first source.. venetoclax : A member of the class of pyrrolopyridines that is a potent inhibitor of the antiapoptotic protein B-cell lymphoma 2. It is used for treamtment of chronic lymphocytic leukemia with 17p deletion.	2.21	1	aromatic ether; C-nitro compound; monochlorobenzenes; N-alkylpiperazine; N-arylpiperazine; N-sulfonylcarboxamide; oxanes; pyrrolopyridine	antineoplastic agent; apoptosis inducer; B-cell lymphoma 2 inhibitor
transforming growth factor beta Transforming Growth Factor beta: A factor synthesized in a wide variety of tissues. It acts synergistically with TGF-alpha in inducing phenotypic transformation and can also act as a negative autocrine growth factor. TGF-beta has a potential role in embryonal development, cellular differentiation, hormone secretion, and immune function. TGF-beta is found mostly as homodimer forms of separate gene products TGF-beta1, TGF-beta2 or TGF-beta3. Heterodimers composed of TGF-beta1 and 2 (TGF-beta1.2) or of TGF-beta2 and 3 (TGF-beta2.3) have been isolated. The TGF-beta proteins are synthesized as precursor proteins.	2.13	1
epz004777 [no description available]	2.11	1	N-glycosyl compound
epz-5676 [no description available]	2.11	1	5'-deoxyribonucleoside
epz005687 EPZ005687: inhibits EZH2 protein; structure in first source	5.39	6	indazoles
epz-6438 tazemetostat: a histone methyltransferase EZH2 inhibitor with antineoplastic activity	6.58	17
gsk343 GSK343: an EZH2 methyltransferase inhibitor. GSK343 : A member of the class of indazoles that is 1-isopropyl-1H-indazole-4-carboxamide in which the nitrogen of the carboxamide group is substituted by a (6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl group and in which the indazole ring is substituted at position 6 by a 2-(4-methylpiperazin-1-yl)pyridin-4-yl group. A highly potent and selective EZH2 inhibitor (IC50 = 4 nM).	4.55	6	aminopyridine; indazoles; N-alkylpiperazine; N-arylpiperazine; pyridone; secondary carboxamide	antineoplastic agent; apoptosis inducer; EC 2.1.1.43 (enhancer of zeste homolog 2) inhibitor
(r)-pfi-2 (R)-PFI-2: a potent and selective inhibitor of SETD7 methyltransferase; structure in first source	2.11	1
osimertinib osimertinib: an EGFR tyrosine kinase inhibitor. osimertinib : A member of the class of aminopyrimidines that is 4-(1-methylindol-3-yl)pyrimidin-2-amine in which one of the amino hydrogens is replaced by a 2-methoxy-4-[2-(dimethylamino)ethyl](methyl)amino-5-acrylamidophenyl group. Used (as the mesylate salt) for treatment of EGFR T790M mutation positive non-small cell lung cancer.	3.51	1	acrylamides; aminopyrimidine; biaryl; indoles; monomethoxybenzene; secondary amino compound; secondary carboxamide; substituted aniline; tertiary amino compound	antineoplastic agent; epidermal growth factor receptor antagonist
1-[(1R)-1-(1-ethylsulfonyl-4-piperidinyl)ethyl]-N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-3-indolecarboxamide (R)-1-(1-(1-(ethylsulfonyl)piperidin-4-yl)ethyl)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1H-indole-3-carboxamide: EZH2 inhibitor	2.11	1	indolecarboxamide
gsk-j4 GSK-J4: a JMJD3 inhibitor; structure in first source	2.89	3	organonitrogen heterocyclic compound
lly-507 LLY-507: inhibits methyltransferase SMYD2; structure in first source. LLY-507 : A secondary carboxamide resulting from the formal condensation of the carboxy group of 5-cyano-2'-{4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl}[biphenyl]-3-carboxylic acid with the amino group of 3-(pyrrolidin-1-yl)propan-1-amine. It is a potent and selective inhibitor of SMYD2 and inhibits the ability of SMYD2 to methylate p53. It serves as a valuable chemical probe to aid in the dissection of SMYD2 function in cancer and other biological processes.	2.11	1

Condition	Indicated	Relationship Strength	Studies	Trials
Brill-Symmers Disease [description not available]	0	2.07	1	0
Diffuse Large B-Cell Lymphoma [description not available]	0	2.07	1	0
Lymphoma, Follicular Malignant lymphoma in which the lymphomatous cells are clustered into identifiable nodules within the LYMPH NODES. The nodules resemble to some extent the GERMINAL CENTER of lymph node follicles and most likely represent neoplastic proliferation of lymph node-derived follicular center B-LYMPHOCYTES.	0	2.07	1	0
Lymphoma, Large B-Cell, Diffuse Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.	0	2.07	1	0
Benign Neoplasms [description not available]	0	8.49	12	1
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	1	10.49	12	1
Congenital Zika Syndrome [description not available]	0	2.25	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	0	4.09	12	0
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	0	2.25	1	0
Experimental Neoplasms [description not available]	0	2.72	2	0
B-Cell Lymphoma [description not available]	0	5.25	3	1
Lymphoma, B-Cell A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.	0	5.25	3	1
Hematologic Malignancies [description not available]	0	4	2	0
Hematologic Neoplasms Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.	0	4	2	0
ER-Negative PR-Negative HER2-Negative Breast Cancer [description not available]	0	2.41	1	0
Triple Negative Breast Neoplasms Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.	0	2.41	1	0
Breast Cancer [description not available]	0	2.66	2	0
Experimental Mammary Neoplasms [description not available]	0	2.41	1	0
Breast Neoplasms Tumors or cancer of the human BREAST.	0	2.66	2	0
Cirrhosis [description not available]	0	3.65	6	0
Fibrosis Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.	0	3.65	6	0
Benign Neoplasms, Brain [description not available]	0	2.6	1	0
Glial Cell Tumors [description not available]	0	2.6	1	0
Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.	0	2.6	1	0
Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)	0	2.6	1	0
Auricular Fibrillation [description not available]	0	2.21	1	0
Atrial Fibrillation Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation.	0	2.21	1	0
Cancer of Head [description not available]	0	2.25	1	0
Head and Neck Neoplasms Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)	0	2.25	1	0
Sclerosis, Systemic [description not available]	0	2.25	1	0
Scleroderma, Systemic A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.	0	2.25	1	0
Postural Orthostatic Tachycardia Syndrome A syndrome of ORTHOSTATIC INTOLERANCE combined with excessive upright TACHYCARDIA, and usually without associated ORTHOSTATIC HYPOTENSION. All variants have in common an excessively reduced venous return to the heart (central HYPOVOLEMIA) while upright.	0	2.25	1	0
Malignant Melanoma [description not available]	0	3.06	4	0
Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)	0	3.06	4	0
Uveal Neoplasms Tumors or cancer of the UVEA.	0	2.25	1	0
Carcinogenesis The origin, production or development of cancer through genotypic and phenotypic changes which upset the normal balance between cell proliferation and cell death. Carcinogenesis generally requires a constellation of steps, which may occur quickly or over a period of many years.	0	2.93	3	0
Cancer of Stomach [description not available]	0	2.31	1	0
Stomach Neoplasms Tumors or cancer of the STOMACH.	0	2.31	1	0
Absence Seizure [description not available]	0	2.31	1	0
Seizures Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.	0	2.31	1	0
Cancer of Skin [description not available]	0	2.84	3	0
Cutaneous T-Cell Lymphoma [description not available]	0	2.31	1	0
Skin Neoplasms Tumors or cancer of the SKIN.	0	2.84	3	0
Lymphoma, T-Cell, Cutaneous A group of lymphomas exhibiting clonal expansion of malignant T-lymphocytes arrested at varying stages of differentiation as well as malignant infiltration of the skin. MYCOSIS FUNGOIDES; SEZARY SYNDROME; LYMPHOMATOID PAPULOSIS; and PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA are the best characterized of these disorders.	0	2.31	1	0
Androgen-Independent Prostatic Cancer [description not available]	0	2.25	1	0
Prostatic Neoplasms, Castration-Resistant Tumors or cancer of the PROSTATE which can grow in the presence of low or residual amount of androgen hormones such as TESTOSTERONE.	0	2.25	1	0
Cancer of Ovary [description not available]	0	4.17	5	0
Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	0	4.17	5	0
Central Nervous System Infection [description not available]	0	2.25	1	0
Hydrophobia [description not available]	0	2.25	1	0
Viral Diseases [description not available]	0	2.25	1	0
Virus Diseases A general term for diseases caused by viruses.	0	2.25	1	0
Cancer of Prostate [description not available]	0	2.84	3	0
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	0	2.84	3	0
Carcinoma, Epidermoid [description not available]	0	2.25	1	0
Cancer of the Tongue [description not available]	0	2.25	1	0
Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)	0	2.25	1	0
Tongue Neoplasms Tumors or cancer of the TONGUE.	0	2.25	1	0
Carcinoma, Small Cell Lung [description not available]	0	2.55	2	0
Cancer of Lung [description not available]	0	3.08	4	0
Lung Neoplasms Tumors or cancer of the LUNG.	0	3.08	4	0
Small Cell Lung Carcinoma A form of highly malignant lung cancer that is composed of small ovoid cells (SMALL CELL CARCINOMA).	0	2.55	2	0
Cirrhosis, Liver [description not available]	0	2.31	1	0
Liver Cirrhosis Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.	0	2.31	1	0
Libman-Sacks Disease [description not available]	0	2.31	1	0
Glomerulonephritis, Lupus [description not available]	0	2.31	1	0
Lupus Erythematosus, Systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.	0	2.31	1	0
Lupus Nephritis Glomerulonephritis associated with autoimmune disease SYSTEMIC LUPUS ERYTHEMATOSUS. Lupus nephritis is histologically classified into 6 classes: class I - normal glomeruli, class II - pure mesangial alterations, class III - focal segmental glomerulonephritis, class IV - diffuse glomerulonephritis, class V - diffuse membranous glomerulonephritis, and class VI - advanced sclerosing glomerulonephritis (The World Health Organization classification 1982).	0	2.31	1	0
Colorectal Cancer [description not available]	0	2.58	2	0
Invasiveness, Neoplasm [description not available]	0	2.31	1	0
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	0	2.58	2	0
Peripheral Nerve Injury [description not available]	0	2.31	1	0
Innate Inflammatory Response [description not available]	0	2.63	2	0
Nerve Pain [description not available]	0	2.31	1	0
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	0	2.63	2	0
Neuralgia Intense or aching pain that occurs along the course or distribution of a peripheral or cranial nerve.	0	2.31	1	0
Peripheral Nerve Injuries Injuries to the PERIPHERAL NERVES.	0	2.31	1	0
Hepatocellular Carcinoma [description not available]	0	2.66	2	0
Cancer of Liver [description not available]	0	2.66	2	0
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	0	2.66	2	0
Liver Neoplasms Tumors or cancer of the LIVER.	0	2.66	2	0
Cancer of Endometrium [description not available]	0	2.15	1	0
Endometrial Neoplasms Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.	0	2.15	1	0
Rhabdomyosarcoma, Embryonal A form of RHABDOMYOSARCOMA arising primarily in the head and neck, especially the orbit, of children below the age of 10. The cells are smaller than those of other rhabdomyosarcomas and are of two basic cell types: spindle cells and round cells. This cancer is highly sensitive to chemotherapy and has a high cure rate with multi-modality therapy. (From Holland et al., Cancer Medicine, 3d ed, p2188)	0	2.17	1	0
Cholangiocellular Carcinoma [description not available]	0	2.15	1	0
Bile Duct Cancer [description not available]	0	2.15	1	0
Metastase [description not available]	0	2.83	3	0
Bile Duct Neoplasms Tumors or cancer of the BILE DUCTS.	0	2.15	1	0
Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.	0	2.83	3	0
Cholangiocarcinoma A malignant tumor arising from the epithelium of the BILE DUCTS.	0	2.15	1	0
Granulocytic Leukemia, Chronic [description not available]	0	2.17	1	0
Leukemia, Myelogenous, Chronic, BCR-ABL Positive Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.	0	2.17	1	0
Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).	0	2.17	1	0
Acute-On-Chronic Liver Failure (ACLF) [description not available]	0	2.17	1	0
Acute-On-Chronic Liver Failure Sudden liver failure in the presence of underlying compensated chronic LIVER DISEASE (e.g., LIVER CIRRHOSIS; HEPATITIS; and liver injury and failure) due to a precipitating acute hepatic insult.	0	2.17	1	0
Graft-Versus-Host Disease [description not available]	0	2.57	2	0
Graft vs Host Disease The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.	0	2.57	2	0
Carcinoma, Non-Small Cell Lung [description not available]	0	2.17	1	0
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	0	2.17	1	0
Disease Exacerbation [description not available]	0	2.55	2	0
Ewing Sarcoma [description not available]	0	2.21	1	0
Sarcoma, Ewing A malignant tumor of the bone which always arises in the medullary tissue, occurring more often in cylindrical bones. The tumor occurs usually before the age of 20, about twice as frequently in males as in females.	0	2.21	1	0
Germinoblastoma [description not available]	0	2.21	1	0
Lymphoma A general term for various neoplastic diseases of the lymphoid tissue.	0	2.21	1	0
Cancer of Colon [description not available]	0	2.57	2	0
Bowel Diseases, Inflammatory [description not available]	0	2.21	1	0
Colitis Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.	0	2.21	1	0
Colonic Neoplasms Tumors or cancer of the COLON.	0	2.57	2	0
Inflammatory Bowel Diseases Chronic, non-specific inflammation of the GASTROINTESTINAL TRACT. Etiology may be genetic or environmental. This term includes CROHN DISEASE and ULCERATIVE COLITIS.	0	2.21	1	0
B-Cell Chronic Lymphocytic Leukemia [description not available]	0	2.21	1	0
Leukemia, Lymphocytic, Chronic, B-Cell A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.	0	2.21	1	0
Adenoma, Basal Cell [description not available]	0	2.11	1	0
Cancer of Pituitary [description not available]	0	2.11	1	0
Adenoma A benign epithelial tumor with a glandular organization.	0	2.11	1	0
Pituitary Neoplasms Neoplasms which arise from or metastasize to the PITUITARY GLAND. The majority of pituitary neoplasms are adenomas, which are divided into non-secreting and secreting forms. Hormone producing forms are further classified by the type of hormone they secrete. Pituitary adenomas may also be characterized by their staining properties (see ADENOMA, BASOPHIL; ADENOMA, ACIDOPHIL; and ADENOMA, CHROMOPHOBE). Pituitary tumors may compress adjacent structures, including the HYPOTHALAMUS, several CRANIAL NERVES, and the OPTIC CHIASM. Chiasmal compression may result in bitemporal HEMIANOPSIA.	0	2.11	1	0
Kahler Disease [description not available]	0	2.55	2	0
Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.	0	2.55	2	0
Acute Myelogenous Leukemia [description not available]	0	2.15	1	0
Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.	0	2.15	1	0
Abnormalities, Autosome [description not available]	0	2.15	1	0
Neuroblastoma A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)	0	2.15	1	0

gsk-2816126

Description

Cross-References

Synonyms (45)

Research Excerpts

Bioavailability

Dosage Studied

Drug Classes (2)

Protein Targets (4)

Potency Measurements

Inhibition Measurements

Biological Processes (52)

Molecular Functions (21)

Ceullar Components (16)

Bioassays (139)

Research

Studies (98)

Study Types

gsk-2816126

Description

Cross-References

Synonyms (45)

Research Excerpts

Bioavailability

Dosage Studied

Drug Classes (2)

Protein Targets (4)

Potency Measurements

Inhibition Measurements

Biological Processes (52)

Molecular Functions (21)

Ceullar Components (16)

Bioassays (139)

Research

Studies (98)

Study Types

Related Drugs (60)

Related Conditions (121)